VIL
Vilon (Lys-Glu) is a synthetic dipeptide bioregulator developed by Professor Vladimir Khavinson. It is designed to support immune function and tissue regeneration through a hypothesized gene-expression mechanism based on in silico and in vitro work.
6 studies referenced · Last reviewed Oct 1, 2026 · Reviewed by The Peptide Dispatch Editorial Team · How we research & label content
Vilon is a compound studied only in animals and lab experiments so far. Vilon (Lys-Glu) is a synthetic dipeptide bioregulator developed by Professor Vladimir Khavinson.
| Half-life | Not established in published research |
|---|---|
| How it's given in studies | Oral, Sublingual |
| Research stage | Preclinical (animal) |
| Dosing | Published research: No published human dosing details10 µg/kg in mice (DMH-induced neoplasia model, route per full text); in vitro concentrations in thymic/pineal cell cultures and fibroblastsCommunity-reportedCommunity-reported: 10–20 mcg oral, oral, Sublingual |
Published-research dosing is what was given in the cited studies (species and units as reported). Community-reported dosing is what users describe, not from clinical studies. Neither is a recommendation. Not medical advice.
Where each point comes from: Clinicalhuman trials and FDA labels Lab / animalrodent, cell and ex vivo studies Community-reporteduser experience and commonly used protocols, not from clinical studies
In plain terms: It is a two-amino-acid peptide proposed to affect gene activity in immune cells, based on cell studies. Proposed mechanism, from cell-culture studies: a Lys-Glu dipeptide proposed to act on gene expression in immune cells. In cultured human and rat thymic cells, Vilon and an analogue increased the lymphocyte differentiation marker CD5 (Sevostianova 2013), and in THP-1 monocytes it modulated proliferative signalling (Avolio 2022).
How to read this: Each item below is an effect observed in research subjects in the cited studies — think of Dexter, our stand-in research subject. These are findings from the literature, not results you should expect, and not medical advice.
Community-reportedCommonly reported doses range from 10 to 20 mcg (oral, sublingual). This is not a recommendation.
Side effects reported in studies are listed separately below.
Community reports are anecdotal, vary widely in product quality and purity, and are not medical advice. Talk to a licensed provider.
Vilon (Lys-Glu or KE) is one of the most studied Khavinson bioregulatory peptides, developed at the Saint Petersburg Institute of Bioregulation and Gerontology. Vilon is classified as an immunomodulatory bioregulator — a dipeptide consisting of lysine and glutamic acid that targets immune system tissues. Based on in silico and in vitro work, it has been hypothesized that these short peptides penetrate the cell nucleus and interact with specific DNA sequences, modulating gene expression related to cell differentiation, proliferation, and apoptosis. In cultured human and rat thymic cells, Vilon showed immunomodulating effects.
Lys-Glu (2 amino acids)
Molecular Weight: 275.3 Da
Molecular Formula: C10H19N3O5
Structure Details: Linear dipeptide consisting of L-lysine and L-glutamic acid. The minimal size enables direct cellular uptake and DNA interaction without receptor-mediated signaling.
New research, FDA peptide updates, and what users are reporting. One email a week. Unsubscribe anytime.
| Peptide | Half-Life | Route | Research Status |
|---|---|---|---|
| Vilon | No published PK data found | Oral, Sublingual | Preclinical (animal) |
| Epitalon | Unknown | Subcutaneous injection | Preclinical (animal) |
| FOXO4-DRI | Unknown | Subcutaneous injection | Preclinical (animal) |
| GDF-11 | Unknown | Subcutaneous injection | Preclinical (animal) |
| Humanin | Unknown | Subcutaneous injection | Preclinical (animal) |
Values reflect figures reported in published research. Compare any peptides side-by-side →
This peptide belongs to the Anti-Aging category. View All Anti-Aging Peptides
Immune
From Our Affiliated Clinic
1836 Wellness is a physician-supervised clinic in Houston, TX. Discussing a compound on this page is not an offer to prescribe or supply it.
See how it works →Disclosure: The Peptide Dispatch and 1836 Wellness are commonly owned by 1836 Wellness LLC. We may benefit financially if you become a client of 1836 Wellness. Learn more.
Dosing, half-life figures, and mechanism descriptions on this page are compiled from peer-reviewed published research, with the species and study type stated where reported. Figures labeled “Dosing used in published research” describe what was given in those studies and do not constitute dosing recommendations for any human use. Each cited paper is listed with DOI and PubMed links in the References section above. Found an error? Contact us.